Speaker: Ken Chapman, MSc, MD, FRCPC, FACP, FERS, University of Toronto, Toronto, ON
Moderator: Isabel Coman, MD, FRCPC, Université de Montréal, Montréal, QC

This presentation will review the selection of biologic therapies (targeting IL-5, IL-4 & IL13, IgE and TSLP) for clinical control in asthma and will also address the challenging question of what to consider when control is not maintained or achieved.

Learning Objectives
At the end of this presentation, attendees will be able to:

  • Review the outcomes achievable with available biologics in severe asthma;
  • Examine the biomarkers used in biologic selection;
  • Consider the long term goals and outcomes of biologic therapies; and
  • Discuss the term “remission” in the context of biologic therapy for severe asthma.

CanMEDS Roles addressed: Communicator, Medical Expert, Scholar

This session is co-developed by the Canadian Thoracic Society and Sanofi Genzyme and is planned to achieve scientific integrity, objectivity and balance.